According to the research report titled ‘Global Antibiotics Market - Analysis By Drug Class (Beta-Lactams, Cephalosporins, Lipopeptide, Others), Mechanism, By Region, By Country (2021 Edition): Market Insights and Forecast with Impact of COVID-19 (2021-2026)’, available with MarketStudyReport, global antibiotics market was worth USD 46.66 billion in 2020 and is anticipated to garner notable returns by the year 2026.

Report findings suggest that ever increasing geriatric population, rising technological advancements, and improved awareness of infectious diseases are the major growth determinants of global antibiotics market outlook.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4383307/

Notably, the tendency for people to overuse antibiotics is raising the possibility that people will develop antimicrobial resistance, making existing medications useless against bacteria that transmit disease. Therefore, increasing emphasis on clinical research for new antibiotics and rising product demand as a result of the expanding population around the world are encouraging market trends.

Additionally, up to 95% of patients who contracted the coronavirus during the pandemic received antibiotics. These included azithromycin and hydroxychloroquine among others, which were successful in treating viral infections, leading to a substantial product demand, which has propelled the industry share in the recent past.

Based on drug class, worldwide antibiotics market is branched into lipopeptide, beta-lactams (penicillin), cephalosporins, and others. In terms of mechanism, the industry is divided into DNA synthesis, protein synthesis, cell wall synthesis, and others.

Regionally the industry trends are studied across North America (U.S., Canada), Europe (Italy, Spain, Germany, France, United Kingdom), LAMEA, and Asia Pacific (China, India, Japan). Among these, North America market held a substantial revenue share in 2020 and is projected to grow significantly over the forecast timeline.

Moving on to competitive landscape, GlaxoSmithKline plc, Johnson & Johnson, Merck KGaA, Amgen Inc., Eli Lily and Company, Novartis International AG, Pfizer Inc., Bayer AG, F. Hoffmann-La Roche AG, and Deinove SA are the leading players influencing the worldwide antibiotics market dynamics. These contenders are undertaking constant research & development for product innovations and are entering into collaborations & partnerships to improve customer reach and strengthen their position in the business sphere.